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Abstract
Background: Sunitinib, a tyrosine kinase inhibitor to treat GIST and mRCC may interact with paracetamol as both
undergo P450 mediated biotransformation and P-glycoprotein transport. This study evaluates the effects of
sunitinib-paracetamol coadministration on liver and renal function biomarkers and liver, kidney, brain, heart and
spleen histopathology. ICR male mice (n = 6 per group/dose) were administered saline (group-A) or paracetamol
500 mg/kg IP (group-B), or sunitinib at 25, 50, 80, 100, 140 mg/kg PO (group-C) or coadministered sunitinib at 25,
50, 80, 100, 140 mg/kg PO and paracetamol IP at fixed dose 500 mg/kg (group-D). Paracetamol was administered
15 min before sunitinib. Mice were sacrificed 4 h post sunitinib administration.
Results: Group-A serum ALT and AST levels were 14.29 ± 2.31 U/L and 160.37 ± 24.74 U/L respectively and
increased to 249.6 ± 222.7 U/L and 377.1 ± 173.6 U/L respectively in group-B; group-C ALT and AST ranged 36.75-
75.02 U/L and 204.4-290.3 U/L respectively. After paracetamol coadministration with low sunitinib doses (group-D),
ALT and AST concentrations ranged 182.79-221.03 U/L and 259.7-264.4 U/L respectively, lower than group-B.
Paracetamol coadministration with high sunitinib doses showed higher ALT and AST values (range 269.6-349.2 U/L
and 430.2-540.3 U/L respectively), p < 0.05. Hepatic histopathology showed vascular congestion in group-B; mild
congestion in group-C (but lesser than in group-B and D). In group-D, at low doses of sunitinib, lesser damage
than in group-B occurred but larger changes including congestion were observed at high sunitinib doses. BUN
levels were higher (p < 0.05) for group-B (33.81 ± 5.68 mg/dL) and group-D (range 35.01 ± 6.95 U/L to 52.85 ±
12.53 U/L) compared to group-A (15.60 ± 2.17 mg/dL) and group-C (range 17.50 ± 1.25 U/L to 26.68 ± 6.05 U/L).
Creatinine remained unchanged. Renal congestion and necrosis was lower in group-C than group-B but was
higher in group-D (p > 0.05). Mild cardiotoxicity occurred in groups B, C and D. Brain vascular congestion occurred
at high doses of sunitinib administered alone or with paracetamol. Hepatic and renal biomarkers correlated with
histopathology signs.
Conclusions: Paracetamol and sunitinib coadministration may lead to dose dependent outcomes exhibiting mild
hepatoprotective effect or increased hepatotoxicity. Sunitinib at high doses show renal, cardiac and brain toxicity.
Liver and renal function monitoring is recommended.
Background
Drug-drug interactions (DDIs) defined as an increase or
decrease in the clinical effect of a given drug due to
interference by another drug, is a significant cause of
morbidity and mortality worldwide [1]. DDIs may result
in adverse clinical events, by decreasing the therapeutic
effect of a drug or by enhancing drug toxicity [2].
Cancer patients present high risk of DDIs as polyphar-
macy for the treatment of cancer as well as other related
syndromes is common [3]. They are also very suscepti-
ble to pain, with moderate or severe pain prevalent in at
least 50% of cancer patients [4,5]. Severe DDIs have
been observed between anti-cancer and pain manage-
ment drugs. Some patients treated with imatinib, a
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generally well-tolerated chemotherapeutic agent, have
experienced renal and hepatic toxicity, which was
increased and fatal in some cases upon coadministration
with paracetamol [6]. Mechanistic studies in animal
models showed changes in imatinib pharmacokinetic
and tissue penetration profiles [7] but most importantly,
an increased of irreversible hepatotoxicity was observed
when both drugs were co-administered [8]. The impor-
tance of interactions with paracetamol is also relevant to
sunitinib: a patient with relapsed metastatic gastrointest-
inal stromal tumour (GIST) treated with sunitinib and
taking also paracetamol and levothyroxine, developed
acute liver failure with fatal outcome [9].
Sunitinib (sunitinib malate; SU11248, SUTENT®) is a
novel oral multitargeted tyrosine kinase inhibitor that
received regular approval from the United States FDA
for the treatment of GIST as well as advanced renal cell
carcinoma (RCC) after progression [10] or intolerance
to imatinib mesylate [11,12]. Sunitinib inhibits various
receptor tyrosine kinases such as the vascular endothe-
lial growth factor receptors (VEGFR) [13], the foetal
liver tyrosine kinase receptor 3 (FLT3) [14], stem-cell
factor receptor (c-KIT) [15], platelet-derived growth fac-
tor receptors PDGFRa and PDGFRb [16], and colony
stimulating factor type 1 receptor (CSF-1R) [17]. Conse-
quently, there is inhibition of angiogenesis, tumor
growth and metastasis [18,19].
In humans, the maximum plasma concentration is
reached 6-12 h after dosing, shows good tissue distribu-
tion, dose proportionality at the range 25-100 mg, and
is highly bound to albumin (95%). Sunitinib is metabo-
lized primarily by the cytochrome P450 3A4 to form
main active metabolite SU12662 that is further metabo-
lized by CYP3A4 [11]. Sunitinib and its metabolite,
which is also highly bound to plasma proteins (90%),
have half-lives of 40-60 h and 80-110 h respectively,
61% of the sunitinib dose is eliminated in the faeces and
around 16% is recovered unchanged in urine [11,17].
Pharmacokinetic studies in mice have shown that suniti-
nib is readily absorbed, presents dose proportionality
and the maximum concentration is achieved within 0.5
to 6 h. Both sunitinib and the main metabolite
(SU12662) are highly bound to mouse plasma proteins
(91% and 95% respectively) with the fraction unbound
independent of the concentration. The elimination half-
life in mice is 1.5 to 7.6 h after oral administration [20].
Although the therapeutic benefits of sunitinib are
great, sunitinib treatment has a significant number of
side effects including fatigue [21], hypertension [11,22],
cardiac dysfunction [23], thyroid dysfunction [23], hand
food skin reaction [19,24], hair depigmentation [19],
asthenia [25], haematologic toxicity [11], and less com-
monly posterior reversible encephalopathy [26], cardio-
toxicity and hypothyroidism [27] and tumour lyses
syndrome [28]. In addition, sunitinib treatment also
caused treatment-emergent laboratory abnormalities
such as a rise in serum alanine transaminase (ALT),
aspartate transaminase (AST) as well as serum creati-
nine concentrations in GIST and mRCC patients which
was mainly Grade 1 and 2 in severity [11,12].
Sunitinib is likely to present a variety of metabolism
based drug-drug interactions Biotransformation of suniti-
nib to form the pharmacologically active N-desethyl meta-
bolite, SU12662 is affected by inhibitor or inducers of
CYP3A4 [11]. Strong CYP3A4 inhibitors such as ketocona-
zole have shown to decrease the metabolism of sunitinib
and to increase plasma sunitinib concentrations [13]. Simi-
larly, CYP3A4 inducers (e.g. rifampin) may decrease suniti-
nib plasma concentrations when the inducer and sunitinib
are co-administered together which lead to subtherapeutic
sunitinib levels [20]. Furthermore, there are some indica-
tions that CYP1A1 and 1A2 may also play a role in suniti-
nib biotransformation [29]. Thus, if it is necessary to
concurrently administer sunitinib and a CYP3A4 inhibitor
or inducer, it is recommended that the dose of sunitinib
should be adjusted (decreased or increased) and that dili-
gent monitoring for toxicity be carried out [11].
Given the nature of the cancer treatment, cancer
patients are likely to be administered pain management
drugs [2,4]. In this study, we used a mouse model to
evaluate the safety and toxicity upon the drug-drug
interaction between sunitinib and paracetamol, a widely
used over the counter analgesic and antipyretic drug.
Though, paracetamol is regarded as a safe drug at thera-
peutic doses; at larger or chronic doses may result in
severe liver and renal injuries [30], including changes in
alkaline phosphatase (ALP), AST, ALT and creatinine
plasma levels [31] which could be additive to those of
sunitinib [10]. Small amounts of paracetamol (~5%)
undergo P450 mediated oxidation to a reactive electro-
philic intermediate, N-acetyl-p-benzoquinoneimine
(NAPQI) [32]. Several P450 isoforms including CYP3A1,
2E1, 1A2 and 2D6 are implicated in the activation of
paracetamol to NAPQI in both humans and rodents
[33]. Furthermore to the hepatotoxicity, potential over-
lapping sunitinib-paracetamol toxicity could also include
renal insufficiency [29] and cardiotoxicity [34].
The current study aims to evaluate the toxicity asso-
ciated with the coadministration of sunitinib and para-
cetamol in mice. A histopathology assessment of the
liver, kidney, spleen, heart and brain is carried out and
correlated with the plasma levels of the biochemical
markers AST, ALT, creatinine and urea.
Methods
Materials
Stock solution of paracetamol (Fluka, France) was pre-
pared in reversed osmosis (RO) water at 30 mg/mL.
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The paracetamol solution was vortex mixed, sonicated
(25 min) and kept warm briefly (50°C) prior to IP
administration to mice. Sunitinib malate (Zhejiang Esun
Chemical Co. Ltd., China) was diluted in RO water to
15 mg/mL, vortex mixed, sonicated (25 min), protected
from light at room temperature until PO administration.
Animals and experimental protocols
Male ICR mice of similar age (8-12 weeks) and weight
(25-35 g) were obtained from University Putra Malaysia
and housed at the International Medical University
(IMU) animal holding facility with 12 h light cycles at
20 ± 2°C for acclimatization. The experimental animals
were provided food and water ad libitum. All animal
procedures had been reviewed and approved by the
IMU Institutional Animal Use and Ethics Committee
preceding the initiation of this study.
Animals were fasted overnight prior to dose adminis-
tration and randomly assigned to each of the four
experimental groups. Mice in group A (n = 6) were
administered saline; mice in group B mice (n = 6) were
administered paracetamol only, 500 mg/kg IP. Group C
was further subdivided into five different dose-groups of
sunitinib only treatment: 25, 50, 80, 100 and 140 mg/kg
administered PO (n = 6 for each dose group). Finally,
mice in group D were co-administered paracetamol (500
mg/kg IP) and sunitinib at different doses: 25, 50, 80,
100 and 140 mg/kg PO (n = 6 each dose group). A feed-
ing needle was used to ensure the full administration of
the dose. Paracetamol was administered 15 minutes
before sunitinib and animals were sacrificed 4 hours
post sunitinib administration by cervical dislocation.
Blood was obtained via cardiac puncture, allowed to
clot, centrifuged (1500 rpm, 10 min, room temperature)
and stored at -20°C until analysis. The liver and kidneys
were excised from the mice and processed for histology
assessment.
Serum biomarkers analysis
Biochemistry analysis of serum ALT and AST was per-
formed using standard assay kits (BiooScientific Corp.,
USA). The concentration in duplicate samples was mea-
sured at 340 nm using a microplate reader (Tecan Infi-
nite F200). Similarly, blood urea nitrogen (BUN) and
creatinine concentration were measured using specific
assay kits (BioAssay Systems, USA) and measured at
490 nm (duplicate samples) in a Dynex OpsysMR
microplate reader.
The effect of the drug combination on the biomarker
levels compared to sunitinib alone treatment was
assessed with the aid of SPSS 16.0 with the significance
level set at p < 0.05. Independent-samples t-test (for sam-
ples normally distributed based on Shapiro-Wilk test) for
pair-wise comparison was performed at each dose of the
sunitinib alone and sunitinib and paracetamol combina-
tion groups. Samples that were not normally distributed
were tested using the Mann Whitney test.
Histopathology assessment of tissues
Processing of tissue samples for histology assessment
followed established procedures. In brief, the tissue sam-
ples were rinsed with 0.9% saline solution, fixed in 10%
formalin. Then the diagonal section of the liver, the
transverse section of the kidneys and heart and the hori-
zontal section of the spleen and the posterior section of
the brain were obtained and processed (Leica TP1020,
Japan) as follows: (1) 10% neutral buffered formalin for
1 h, twice; (2) 70% alcohol for 1.5 h; (3) 80% alcohol for
1.5 h; (4) 90% alcohol for 1.5 h; (5) absolute alcohol for
1.5 h, twice; (6) xylene for 1.5 h, twice; (7) in molten
wax at 65°C for 2.5 h two changes. The processed tis-
sues were embedded in paraffin and sectioned at 4
microns thickness, placed on frosted glass slides and
dried on a 70°C hot plate for 30 minutes.
The tissues were stained using the hematoxylin and
eosin (H&E) stains. The sections were dewaxed in two
changes of xylene (3 min each), hydrated in two changes
of 100% ethanol, followed by 90% ethanol and 70% etha-
nol, for 3 min each, rinsed with water (3 min) and
stained. The stained tissues were dehydrated with 70%
ethanol followed by 90% ethanol, placed in two changes
of 100% ethanol for 3 minutes each and cleaned with
two changes of xylene (3 min each).
Histopathology changes were observed and grouped
based on two main criteria: vascular changes including
vessel congestion, extravasation of red blood cells and
hematoma formation; and necrotic changes including
necrosis, fibrosis, nuclear changes, abscesses and cell
regeneration. The morphological changes were assessed
semi-quantitatively, blind by two independent assessors
and graded as follows: No change - 0 (no distinguishable
change, 0%); mild change - 1 (initiation of changes, up
to 30%); moderate change - 2 (patent changes, 31-60%);
severe change - 3 (wide spread changes, 61-100%) [35].
Then, using SPSS 16.0, the Mann-Whitney test was
used for pair-wise comparison between the sunitinib
alone group and the combination group at each dose.
The differences were considered significance if p < 0.05.
Results
The changes in toxicity associated with the coadminis-
tration of sunitinib and paracetamol were assessed at
biochemistry and histopathology level. The serum con-
centrations of the biochemical markers ALT, AST, urea
and creatinine were obtained to evaluate the liver and
renal functions. In addition, the histopathological
changes in the target organs such as liver, kidneys,
heart, brain and spleen were semi-quantitatively graded.
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Liver and renal function biomarkers
The mean serum AST level in untreated mice (Table 1),
vehicle control group was 160.37 ± 24.74 U/L but it was
2-fold greater (377.09 ± 173.55 U/L) in mice treated
with paracetamol (Figure 1). Mice treated with increas-
ing doses of sunitinib showed a gradual elevation of
AST serum concentration (range 204.64 - 290.28 U/L)
following rising sunitinib doses. However, the pattern
observed upon coadministration of sunitinib and parace-
tamol was different. At lower doses of sunitinib, the
mean AST serum concentrations were slightly higher
than those of the sunitinib alone group, but lower than
the concentration found upon administration of parace-
tamol alone: 31.1% and 29.9% for the 25 mg/kg and 50
mg/kg dose respectively. However, a large increase in
AST concentrations were observed at the higher doses
of sunitinib coadministered with paracetamol which was
statistically significant at 100 mg/kg (p < 0.01) and 140
mg/kg (p < 0.001) doses.
Similarly, the serum ALT concentrations were mea-
sured (Figure 1, Table 1). In the vehicle control group
the ALT serum concentration was 14.29 ± 2.31 U/L and
it slightly increased in the sunitinib treatment group
(range 36.75 - 75.02 U/L). As expected, a large increase
in serum ALT levels was observed after administration
of paracetamol only (249.60 ± 222.72 U/L) although it
did not reach statistical difference with the baseline con-
trol value, probably due to the large variability. Parallel
to AST, there was a significant ALT elevation in the
coadministration group at 100 mg/kg (p < 0.05) and 140
mg/kg (p < 0.01) doses of sunitinib. In addition, at
lower doses of sunitinib with paracetamol coadministra-
tion, the ALT levels were found lower than those in the
group that received paracetamol only: at 25 mg/kg the
ALT concentration was 26.8% lower and at 50 mg/kg it
was 25.2% lower. However, it did not reach statistical
significance probably due to the variability in the para-
cetamol group.
Renal biomarkers included the blood urea nitrogen
(BUN) and creatinine (Figure 1, Table 1). The BUN
concentrations were slightly increased (range 17.50 -
26.68 mg/dL) after administration of sunitinib in com-
parison to those of baseline control group (15.60 ± 2.17
mg/dL) with significant differences (p < 0.05) with the
control group at 25, 80 and 140 mg/kg sunitinib doses.
A significant increase in BUN concentration was
observed in the group administered paracetamol only
(33.81 ± 5.68 mg/dL, p < 0.05). In addition, all dose
groups of the coadministration group showed differ-
ences with the respective sunitinib group dose (p <
0.05). As for creatinine concentrations (Figure 1), there
was no significant difference between the serum concen-
trations in the baseline control group (0.529 ± 0.044
mg/dL) and those found in mice treated with increasing
doses of sunitinib alone (range 0.528 - 0.594 mg/dL).
However, administration of paracetamol alone increased
21% the creatinine serum concentration. Finally,
the combination treatment sunitinib-paracetamol did
not show any significant rise in mean creatinine
concentrations.
Histopathology in liver tissue
The histopathology assessment in liver was performed
for all groups. Mice in the vehicle (saline) control
group showed normal, well defined histological struc-
tures without any signs of vascular or inflammatory
changes. The histopathology analysis of the liver
revealed signs of toxicity after administration of parace-
tamol. This toxicity was significant (p < 0.05) in com-
parison with baseline group and included mild vascular
Table 1 Mean ± SE serum biomarker concentration for each of the study arms
Group Dose (mg/kg) AST ALT BUN Creatinine
SUN PCM (U/L) (U/L) (mg/dL) (mg/dL)
Vehicle - - 160.4 ± 24.7 14.29 ± 2.31 15.6 ± 2.17 0.529 ± 0.044
PCM - 500 377.1 ± 173.6 249.6 ± 222.7 33.81 ± 5.68 0.644 ± 0.110
Sunitinib 25 - 204.6 ± 50.3 61.40 ± 26.57 20.08 ± 2.54 0.535 ± 0.033
50 - 204.4 ± 49.4 36.75 ± 12.15 17.5 ± 1.25 0.594 ± 0.082
80 - 290.3 ± 77.7 75.02 ± 20.37 19.71 ± 0.58 0.528 ± 0.064
100 - 243.0 ± 66.4 47.61 ± 24.50 17.62 ± 0.94 0.533 ± 0.060
140 - 239.5 ± 65.9 50.89 ± 18.90 26.68 ± 6.05 0.559 ± 0.051
Sunitinib 25 500 259.7 ± 67.4+ 182.8 ± 64.91* 38.24 ± 6.08* 0.514 ± 0.089
& PCM 50 500 264.4 ± 104.9 186.7 ± 124.3 38.89 ± 8.69* 0.520 ± 0.143
80 500 430.2 ± 163.6 221.0 ± 113.0 35.01 ± 6.95* 0.591 ± 0.084
100 500 469.8 ± 90.3+* 349.2 ± 132.4* 43.75 ± 8.37* 0.502 ± 0.103
140 500 540.3 ± 76.1+* 269.6 ± 72.6* 52.85 ± 12.53+* 0.627 ± 0.060
+ p < 0.05 in comparison with group B (paracetamol).
* p < 0.05 in comparison with group C (sunitinib alone).
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congestion and moderate inflammatory changes with
congested sinusoids, nuclear changes, and centrilobular
necrosis (Figure 2). Treatment with increasing doses of
sunitinib alone resulted in mild vascular and inflamma-
tory changes (not significant in comparison with base-
line control) including microabscess formation and
cytoplasmic condensation indicating early cellular
injury (Figure 3). In the combination treatment, there
was moderate to severe vascular and sinusoidal conges-
tion, as well as inflammatory changes with extensive
necrosis at high doses of sunitinib that were statistically
significant in comparison with the sunitinib alone
group (p < 0.05) at 80, 100 and 140 mg/kg (Figure 4
and 5). However, at lower doses of sunitinib coadminis-
tered with paracetamol, there were mild vascular
changes comparable to those in the group treated with
paracetamol and mild inflammatory changes which
were even less severe than those observed after parace-
tamol administration (Figure 5).
Renal histopathology
Normal histology of the glomerulus and tubules was
found in kidney tissue of mice that received saline vehi-
cle only (Figure 6). Paracetamol induced mild vascular
and inflammatory changes with signs of vascular conges-
tion, tubular necrosis and glomerular atrophy, which is a
Figure 1 Liver and renal function biomarkers. Change in biomarkers upon administration of saline vehicle (baseline control), paracetamol,
sunitinib at several doses or combination treatment paracetamol and sunitinib. (* p < 0.05 bewteen groups C and D based on t-test except for
ALT that Mann Whitney test was used).
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Figure 2 Histopathological changes in liver after administration of paracetamol. Representative microphotographs of liver tissue sections
(H&E staining, 200x) showing (A) nuclear pyknosis (arrows), vascular congestion and fatty change in liver parenchyma and (B) areas of
centrilobular necrosis and vascular congestion involving the portal triad and dilation of central vein indicating backflow of circulation.
Figure 3 Histopathological changes in liver after administration of sunitinib (H&E staining). A: Photomicrograph (200x) of liver section
after administration of 25 mg/kg sunitinib showing vascular congestion (arrows) in the central veins and red blood cells pooling in the
sinusoids. B: Liver section (400x) after administration of sunitinib 25 mg/kg. Notice a microabscess (circle) involving a few hepatocytes with
inflammatory cells and necrotic debris. Hepatocytes undergoing cytoplasmic condensation and regeneration are also observed (arrow). C:
Photomicrograph (100x) from the sunitinib 80 mg/kg group showing vascular congestion involving the central veins amidst hepatocytes
surrounded by dilated sinusoids. D: Photomicrograph (400x) from the sunitinib 100 mg/kg group. Notice the hepatocytes in various stages of
cytoplasmic condensation, suggesting early stages of cell injury.
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degenerative phenomenon (Figure 6). Mice treated with
sunitinib alone only showed mild vascular changes in
the kidneys comparable to those observed upon admin-
istration of paracetamol, but no signs of inflammatory
changes were observed, except at the highest dose of
sunitinib (140 mg/kg) where some tubular necrosis was
noted (Figure 7). In the combination treatment group,
the vascular changes increased (p < 0.05 above 80 mg/
kg dose in comparison to group C) from mild to moder-
ate damage as the sunitinib dose increased (Figure 7 and
8). However, the inflammatory changes were mild, simi-
lar to those in group B at low sunitinib doses and
become moderate changes at the highest sunitinib dose
(140 mg/kg) where tubular casts were observed (Figure
8) and were statistically significant above 50 mg/kg
doses).
Histopathology findings in heart, brain and spleen
The heart tissues from the vehicle control group showed
normal cardiomyocytes with no vascular or inflammatory
changes (Figure 9). The cardiovascular tissue from mice
treated with paracetamol showed mild vascular congestion
and inflammatory changes such as myocyte coagulation
(Figure 9). Sunitinib treatment resulted in mild vascular
congestion (Figure 9) but no inflammatory changes were
noted. The histopathology of the heart in the coadminis-
tration treated mice showed moderate vascular and
inflammatory changes at 100 and 140 mg/kg which were
significant (p < 0.05) and included congested and dilated
blood vessels (Figure 9). However, mice treated with the
lower doses of sunitinib alone showed reduction in cardio-
toxicity in relation to the paracetamol group, which ranged
from no damage to moderate damage at the 25 - 80 mg/kg
doses of sunitinib (Figure 10).
The neurohistopathology assessment demonstrated
normal neuronal cells with no vascular or inflammatory
changes after administration of saline or paracetamol.
Some congestion of vessels at the ‘cortical junction’ as
well as evidence of liquefactive necrosis was observed in
mice treated with sunitinib alone at low doses (p < 0.05
Figure 4 Histopathological changes in liver after coadministration of sunitinib and paracetamol (H&E staining). Photomicrographs of liver
sections after coadministration of sunitinib (25 mg/kg) and paracetamol. A: (200x) damaged hepatocytes with areas of fatty change (arrows),
sinusoid congestion and central vein dilation. B: (400x) red blood cells accumulated around the draining pathways of the central vein (arrow)
suggesting backflow congestion. C: fatty change in the cytoplasm and pyknotic nuclei (arrows). D: photomicrograph (200x) after combination
treatment of sunitinib 50 mg/kg and paracetamol showing a focal area of microabscess (circle) consisting of inflammatory cells and necrotic debris.
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at 25 and 80 mg/kg) but the toxicity decreased at high
doses (Figure 11). The combination treatment group D,
overall, showed less neurotoxicity than group C at low
doses of sunitinib with lesser vascular congestion but a
raise of neurotoxicity including generalised congestion
was seen at high doses (p < 0.05), of sunitinib in combi-
nation with paracetamol (Figure 12).
Finally, the histology assessment in the spleen did not
reveal any vascular changes in the paracetamol treated
group, sunitinib treated mice or the sunitinib-
paracetamol drug combination group. Only a very slight
splenic congestion was observed at the highest dose of
140 mg/kg (p < 0.05) sunitinib-paracetamol combination
(Figure 13). Furthermore, no inflammatory changes were
observed at any dose in the sunitinib alone group, para-
cetamol alone group, or in the sunitinib plus paraceta-
mol drug combination group.
Discussion
The histopathological changes in the liver, kidneys,
heart, brain and spleen together with hepatic and renal
function biochemical markers were evaluated after coad-
ministration of sunitinib with paracetamol. Clinical trials
in mRCC patients had shown that liver and renal func-
tions are affected by sunitinib leading to elevated AST,
ALT and creatinine plasma levels [11]. Furthermore, the
wide-spread use of paracetamol in cancer patients as an
effective pain management drug with its potential renal
and hepatotoxicity may elevate the risk of organ dys-
function after coadministration [10], a phenomenon
observed with other anticancer drugs [9].
Possible hepatoprotective effect of sunitinib
In the current study, a significant rise in serum AST and
ALT levels was observed after administration IP of 500
mg/kg paracetamol dose in comparison with the base-
line control group (Figure 1). This is a consistent finding
with previous studies where it was shown that the rise
in serum AST and ALT concentrations peak 4 h after
administration of 500 mg/kg paracetamol IP [36]. In
addition, the histopathological analysis also showed vas-
cular and inflammatory changes (Figure 2) such as cen-
trilobular necrosis, congested sinusoids and nuclear
changes which were similar to other studies [35]. In
contrast, after sunitinib was administered at escalating
doses, the serum AST and ALT levels were only slightly
elevated and mild liver damage with slight vascular con-
gestion and signs of hepatocyte regeneration were found
(Figure 3). No studies have yet been conducted on the
histopathology changes caused by sunitinib administra-
tion; however, it was observed in clinical studies con-
ducted on patients receiving sunitinib for the treatment
of GIST or mRCC a slight increase in ALT and AST
serum concentrations [11,12]. In addition, the combina-
tion treatment group showed. lower AST and ALT
serum levels in comparison to group B (paracetamol,
500 mg/kg, IP) at low doses of sunitinib coadministered
with paracetamol. However, at higher doses of sunitinib
in group D, both the AST and ALT levels were signifi-
cantly increased (Figure 1). The histopathological analy-
sis of the hepatic tissue showed a similar trend. At low
doses of sunitinib coadministered with paracetamol, the
hepatic morphological changes showed less severe
damage compared to group B. Meanwhile, at higher
Figure 5 Hepatic vascular and inflammatory changes. Graphical
representation of the score and grading of the vascular and
inflammatory changes observed in the liver after administration of
saline vehicle (baseline control), paracetamol, sunitinib at several
doses or combination treatment paracetamol and sunitinib (* p <
0.05 bewteen groups C and D based on Mann Whitney test).
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doses of sunitinib (group D), a greater severity of the
morphological changes such as vascular congestion,
fatty change, and centrilobular necrosis were observed,
indicating increased toxicity (Figure 5).
The biochemical and histopathological findings of
the liver were unexpected. Low doses of sunitinib and
paracetamol in the coadministration group seemed to
decreased paracetamol hepatotoxicity, suggesting that
sunitinib may have some level of hepatoprotective
effect as previously suggested [10]. However, in the
present study, the protective effect seemed to be oblit-
erated at higher doses of sunitinib coadministered with
paracetamol.
Therefore, a preliminary mechanistic working-hypoth-
esis based on the paracetamol metabolic pathway may be
postulated in the attempt to explain the differential effect
between the low and the high doses of sunitinib upon
coadministration with paracetamol. The metabolism of
paracetamol is mediated by CYP2E1, 1A2 and 3A4 to
form the toxic metabolite NAPQI [37], while sunitinib is
metabolized by CYP3A4, 1A1 and 1A2 to form the active
metabolite SU12662 [13,30]. Thus, as both sunitinib and
paracetamol share the same isoenzyme CYP3A4 for their
metabolism, the generation of NAPQI from this pathway
may be decreased, resulting in less toxic effects. However,
as the dose of sunitinib coadministered with paracetamol
is increased, the protective effect is reversed and greater
toxicity is observed. This could be explained if sunitinib
or its metabolite affect the glutathione mediated detoxifi-
cation pathway of paracetamol, either by binding to glu-
tathione or by decreasing its available pool reducing the
capacity to protect the hepatocytes from the electrophilic
damage caused by NAPQI [38]. Then, even after lower
generation of NAPQI , the depletion of glutathione avail-
able would lead to NAPQI accumulation and toxicity.
Although conjugation of sunitinib with glutathione is not
Figure 6 Histopathological changes in kidney after administration of paracetamol (H&E staining). Photomicrographs of kidney tissue
sections after administration of vehicle or paracetamol. A: (100x) saline group showing normal orientation of nephrons with adequate glomeruli
and well spaced tubules. B: Photomicrograph (200x) showing areas of red blood cells extravasating into the interstitium and amidst the spaces
between the tubules. C: photomicrograph (400x) showing congested vasculature (arrow) in the juxtaglomerular spaces. D: photomicrograph
(200x) where dilated spaces filled with accumulated blood cells, suggesting focal haemorrhages can be observed.
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reported in the literature, sunitinib is a substrate and a
competitive inhibitor of a glutathione-conjugate trans-
porter and may decrease the availability of glutathione in
the hepatocytes [39]. A similar mechanistic explanation
has been proposed for cisplatin, a chemotherapy drug
which binds to glutathione [40]. Although the current
experiment was not designed to evaluate the potential
hepatoprotective effect of sunitinib in a paracetamol
induced liver toxicity model, the results point out
towards a certain protective effect as observed previously
(10). Further studies need to be conducted to clarify the
Figure 7 Representative histopathological changes in
kidney after administration of sunitinib alone or
coadministered with paracetamol (H&E staining).
Photomicrographs of kidney tissue sections after administration
of sunitinib or sunitinib and paracetamol. A: (200x)
photomicrograph after administration of sunitinib (50 mg/kg)
showing glomeruli atrophy (yellow arrow). Notice the reduction
in size and cellularity, when compared to normal glomeruli
(blue arrow). B: photomicrograph (100x) after administration of
sunitinib (80 mg/kg) showing glomerular atrophy admixed with
congested spaces and extravasated red blood cells in the
interstitium. C: photomicrograph (200x) after coadministration
of sunitinib (140 mg/kg) and paracetamol, showing tubules
filled with casts in the lumen (arrow).
Figure 8 Renal vascular and inflammatory changes. Graphical
representation of the score and grading of the vascular and
inflammatory changes observed in renal tissue after administration
of saline vehicle (baseline control), paracetamol, sunitinib at several
doses or combination treatment paracetamol and sunitinib (* p <
0.05 bewteen groups C and D based on Mann Whitney test).
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Figure 9 Photomicrographs of representative histopathological changes in heart tissue (H&E staining). Photomicrographs of kidney
tissue sections after administration of sunitinib or sunitinib and paracetamol. A: photomicrograph (100x) from heart tissue from the control
saline group showing the ventricular wall with normal orientation of healthy cardiomyocytes. B: photomicrograph (200x) from the saline vehicle
group showing the normal morphology of the muscle fibers with abundant wavy cytoplasm and small nuclei. C: photomicrograph (200x) after
administration of paracetamol showing numerous congested vessels (arrows) amidst the muscle fibres. D: photomicrograph (200x) showing
congested and dilated blood vessels (arrows) in the heart muscle filled with red blood cells after administration of 50 mg/kg sunitinib. E:
photomicrograph (200x) showing congested and dilated blood vessels in the heart muscle after coadministration of 80 mg/kg sunitinib with
paracetamol. F: photomicrograph (200x) showing further congested and dilated blood vessels in the heart muscle and filled with red blood cells
after coadministration of sunitinib (100 mg/kg) and paracetamol.
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intertwining relationship between paracetamol, sunitinib,
the formation of NAQPI and the glutathione cellular
concentration.
Renal toxicity
The biochemical markers BUN and creatinine were used
to evaluate renal function. Administration of 500 mg/kg
paracetamol IP caused a significant rise in BUN concen-
trations (Figure 1) which was consistent with other stu-
dies after oral [41] or IP administration [42] of
paracetamol, although the biomarker concentrations
were measured at a later time point (24 h). The toxicity
associated with paracetamol also resulted in glomerular
atrophy and necrosis of the tubules, similar to those
observed in acute tubular necrosis in both proximal and
distal parts of the tubules including damage to the glo-
merulus (Figure 6) [41,43]. Administration of sunitinib
caused a small elevation of BUN levels and mild vascu-
lar congestion at the highest dose (140 mg/kg). When
sunitinib was coadministered with paracetamol, the
BUN plasma levels and the histopathological analysis at
low doses of sunitinib were similar to those of paraceta-
mol treated group suggesting that the toxicity may be
due to the presence of paracetamol only. Besides, the
circulating paracetamol toxic metabolite may be gener-
ated in the liver as well at the proximal tubule of the
kidney by the CYP2E1 enzyme [44]. However, at higher
doses of sunitinib, the BUN plasma concentrations rose
above those of observed in the groups that were given
paracetamol or sunitinib alone and was accompanied by
increased vascular and inflammatory changes (Figure 8).
This suggests that the renal toxicity observed at higher
doses may be a combined effect of the toxicity contribu-
ted by sunitinib and paracetamol.
A significant correlation between the BUN levels and
kidney morphological changes was present (Table 2).
However, the creatinine biomarker did not show any
correlation with the histopathological findings. This
finding is similar to other studies where no significant
rise in plasma creatinine level was noted 6 h after para-
cetamol administration at higher doses [45]. Thus, crea-
tinine plasma levels may not be an early indicator of
renal toxicity, even though histopathological changes
were observed in the kidneys [46,47].
The protective effect of sunitinib on paracetamol toxi-
city was not as obvious in the kidneys as it was in the
liver. This may be due to additional mechanisms contri-
buting to paracetamol toxicity such as prostaglandin
synthetase and N-deacetylase enzymes [29], different
mechanisms and sensitivity of the renal tissue [48] or
different in situ biotransformation [49]. Consequently,
sunitinib may not be able to affect the paracetamol
metabolic pathway in the kidneys.
Associated toxicity in heart, spleen and brain
Several studies carried out in humans with sunitinib
have reported signs of toxicity in other organs besides
the liver or the kidneys [50].
Figure 10 Vascular and inflammatory changes in heart tissue. Graphical representation of the score and grading of the vascular and
inflammatory changes observed in cardiac tissue after administration of saline vehicle (baseline control), paracetamol, sunitinib at several doses
or combination treatment paracetamol and sunitinib at several doses (* p < 0.05 bewteen groups C and D based on Mann Whitney test).
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In the present study, sunitinib treatment showed vascu-
lar congestion in the heart with no inflammatory changes
in the cardiomyocytes (Figure 9). These results are consis-
tent with observations in clinical studies where the cardio-
toxicity did not present inflammatory or fibrotic changes
in patients [23]. Some of the mechanisms of cardiotoxicity
for other tyrosine kinase inhibitors have been determined,
but the mechanism of cardiotoxicity due to sunitinib is yet
to be discovered [51]. Although paracetamol cardiotoxicity
is rare, non-specific ECG changes, bradycardia, pericardial
rub and endocarditis, were observed in patients [52].
Furthermore, subendocardial haemorrhages and muscle
necrosis was noted in the autopsies of two patients who
died from paracetamol overdose [53]. Mice in the parace-
tamol treatment group showed signs of toxicity with con-
gested vessels and focal myocyte coagulation (Figure 9). It
has been suggested that these toxicity pattern may be
associated with paracetamol metabolite and free radical
NAPQI, resulting in myocyte glutathione depletion,
damage to the myocardium and breakdown of endothe-
lium-derived vascular relaxing factor (EDRF), leading to
functional coronary insufficiency [33] and myocyte coagu-
lative necrosis which has been observed in our study and
in previous ones [52]. The combination treatment also
showed dose dependent cardiac toxicity with a pattern
similar to that observed in liver: At low doses of sunitinib
in the drug combination, the scoring of the morphological
changes was below that of paracetamol alone, while the
toxicity increased slightly at the higher doses of sunitinib
with paracetamol. Extrahepatic paracetamol toxicity in
kidneys, lungs and nasal glands has been attributed to
circulating NAPQI generated in the liver [49]. Thus, it is
possible to suggest that the cardiotoxicity may be asso-
ciated with the generation of toxic metabolite by the liver
Figure 11 Photomicrographs of representative histopathological changes in brain tissue (H&E staining, 100x). Photomicrographs of
representative brain regions after administration of sunitinib or combination treatment of sunitinib and paracetamol. A: photomicrograph
showing zones of congested blood vessels of moderate to small size (arrows) bordering the cellular areas after administration of sunitinib 50
mg/kg dose. B: photomicrograph from the sunitinib 80 mg/kg group showing vascular congestion in the brain. C: photomicrograph from the
combination treatment sunitinib (50 mg/kg) and paracetamol group showing vascular congestion (arrows) in the brain. D: photomicrograph
showing vascular congestion in the brain after coadministration of sunitinib 100 mg/kg and paracetamol.
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and would follow the liver pattern of toxicity as proposed
with the working hypothesis [36]. Further studies, includ-
ing cardiac biomarkers such as CK-MB and quantification
of circulating NAPQI are needed to assess sunitinib effects
on the cardiac toxicity.
There was no evidence of neurotoxicity associated
with paracetamol [54]. However, sunitinib caused vascu-
lar and inflammatory changes including vascular conges-
tion and early signs of liquefactive necrosis (Figure 11).
Previous animal studies have confirmed that sunitinib
and its metabolite penetrate the brain up to 30%-40% of
plasma concentrations in monkeys [55], 4-7 times the
plasma concentration in mice [21]. In fact, some
patients developed cognitive and behavioural changes
during sunitinib treatment that included disorientation,
confusion and word-finding difficulties [56] and poster-
ior reversible encephalopathy syndrome in one patient
[27]. These symptoms were reversible upon sunitinib
discontinuation [27,56] but the mechanisms leading the
development of neurological symptoms due to tyrosine
kinase inhibition remain unknown [54]. At low doses of
Figure 12 Vascular and inflammatory changes in brain. Graphical representation of the score and grading of the vascular and inflammatory
changes observed in brain tissue after administration of saline vehicle (baseline control), paracetamol, sunitinib at several doses or combination
treatment paracetamol and sunitinib at several doses (* p < 0.05 bewteen groups C and D based on Mann Whitney test).
Figure 13 Photomicrographs of the histopathology of the
spleen (H&E staining). Histopathological changes were observed
only at the highest dose of sunitinib (140 mg/kg) coadministered
with paracetamol. A: photomicrograph (100x) from the control
saline group showing normal morphology of the spleen including
the red and white pulp areas. B: photomicrograph (200x) after
coadministration of sunitinib 140 mg/kg and paracetamol showing
areas of cellularity admixed with mild congestion.
Table 2 Significant values of the correlation between
biomarkers and liver and renal histopathological changes
based on Spearman rank correlation test
Biomarker Liver changes Kidney changes
Vascular Inflammatory Vascular Inflammatory
AST p < 0.01 p < 0.01 n/a n/a
ALT p < 0.01 p < 0.01 n/a n/a
BUN n/a n/a p < 0.01 p < 0.01
Creatinine n/a n/a p > 0.05 p > 0.05
The correlation is significant if p < 0.01.
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sunitinib coadministered with paracetamol, the morpho-
logical changes were lesser to those observed in the
sunitinib alone treatment group which is consistent with
previous findings suggesting anti-oxidant and anti-
inflammatory effect of paracetamol on the cerebrovascu-
lature due to menadione-induced oxidative stress [57].
Furthermore, the decreased toxicity observed in this
study may be supported by lower sunitinib brain con-
centration after coadministration with paracetamol
observed in a separate study [58,59]. However, when
high doses of sunitinib were administered with paraceta-
mol, the vascular congestion severity increased and
liquefactive necrosis was noted suggesting other
mechanisms of toxicity which are unknown.
Finally, there were no signs of toxicity in the spleen in
all groups except at 140 mg/kg of sunitinib coadminis-
tered with paracetamol which mild splenic congestion
was observed (Figure 13). Similar splenic congestion was
also observed after barbiturate administration in dogs
[60]. The absent of toxicity, except at a very high dose,
may encourage the development of advanced particulate
delivery systems to target specific sunitinib-sensitive
tumours without the risk of toxicity associated to their
accumulation in the spleen [61,62].
Correlation between biomarkers and histopathological
findings
Of especial interest is the ability to establish a correlation
between toxicology and biomarkers that can provide early
detection of toxicity and allow prompt intervention. In this
study, we found a significant correlation (p < 0.01) between
the liver biochemical markers (ALT and AST) and the liver
histopathology for both vascular (p < 0.01) and inflamma-
tory (p < 0.01) changes (Table 2). A significant correlation
was also found between the BUN plasma levels and kidney
morphological changes be it vascular (p < 0.01) or inflam-
matory (p < 0.01) changes. This suggests that ALT and
AST may be used as early indicators for the detection of
acute liver damage as well as BUN for renal toxicity in the
treatment of sunitinib and paracetamol.
However, there was no correlation with creatinine
plasma levels. This was found consistent with other stu-
dies where no significant rise in plasma creatinine level
was noted 6 hours after paracetamol administration at
higher dose [44]. Thus, this finding suggests that unlike
BUN, creatinine may not be an early indicator of renal
toxicity or that 4 hours is too early to observe any sig-
nificant rise in creatinine levels [30,45].
Conclusions
The present study has found changes in the toxicity pat-
tern with the coadministration of paracetamol with
sunitinib compared to sunitinib alone.
Sunitinib administration resulted in mild toxicity in
the liver, kidneys, heart and brain, asserting its safety at
low doses. The coadministration of sunitinib and para-
cetamol had dose and differential effects in liver, kidneys
and heart. However, no toxicity was observed in the
spleen and neurotoxicity was observed only when suniti-
nib was administered alone. Sunitinib also seemed to
display dose dependent, protective effects on paraceta-
mol toxicity, especially regarding hepatotoxicity, which
may be related to the fact that both paracetamol and
sunitinib share the biotransformation pathway.
A significant correlation between the liver biomarkers
(ALT and AST) and hepatic histopathological changes was
found as well as between the renal biomarker BUN and
kidney morphological changes. However, creatinine levels
did not show a correlation with any study group. This sug-
gests that ALT, AST and BUN may be valid early indica-
tors for monitoring emerging toxicity in patients
undergoing treatment with sunitinib and paracetamol.
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